Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database

References

• Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the Non-Hodgkin’s lymphomas. Distribution of the major subtypes differs by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 1998; 9: 717–720.
   PubMed Web of Science ®Google Scholar
• Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood 2013; 122: 981–987.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of national Lymphocare Study. J Clin Oncol 2009; 27: 1202–1208.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Vitolo U, Kimby E, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 2013; 24: 561–576.
   PubMed Web of Science ®Google Scholar
• Nicolas-Virelizier E, Segura-Ferlay C, Ghesquieres H, et al. Impact of the introduction of rituximab in first-line follicular lymphoma: A retrospective study of 247 unselected patients referred to a single institution with a long term follow-up. Hematol Oncol 2015; 33: 1–8.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Marchetti M, Billio A, et al. SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. Am J Hematol 2013; 88: 185–192.
   PubMed Web of Science ®Google Scholar
• Griffin MM, Morley N. Rituximab in the treatment of non-Hodgkin’s lymphoma – a critical evaluation of randomized controlled trials. Expert Opin Biol Ther 2013; 13: 803–811.
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvilli A, Sales G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011; 103: 1799–1806.
   PubMed Web of Science ®Google Scholar
• Rituximab FDA approval revision 2011. Available from: http://www.acessdata.fda.gov/drugsatfda_docs/label/2011/103705s5332lbl.pdf
   Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42–51.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of Rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent Non-Hodgkin’s lymphoma – A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088–1095.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402. J Clin Oncol 2014; 32: 3096–3102.
   PubMed Web of Science ®Google Scholar
• Yared J, Kimball A, Baer MR, et al. Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma. Clin Lymphoma Myeloma Leuk 2013; 13: 253–257.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103: 4416–4423.
   PubMed Web of Science ®Google Scholar
• Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009; 27: 1607–1614.
   PubMed Web of Science ®Google Scholar
• Witzens-Harig M, Foa R, Di Rocco A, et al. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. Ann Hematol 2014; 93: 1717–1724.
   PubMed Web of Science ®Google Scholar
• Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for reccurent infections. Clin Lymphoma Myeloma Leuk 2013; 13:106–111.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 patients. Leuk Lymphoma 2006; 47: 1013–1017.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Ollberding NJ, Villines D, et al. A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas. Leuk Lymphoma 2014; 55: 1288–1294.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of tumours of haematopoietic and lymphoid tissues; 4th Edition. Lyon: International Agency for Research on cancer (IARC); 2008.
   Google Scholar
• Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on no Hodgkin’s disease staging classification. Cancer Res 1971; 31: 1860–1861.
   PubMed Web of Science ®Google Scholar
• Sykorova A, Belada D, Smolej L, et al. Staging of non-Hodgkin’s lymphoma –recommendations of the Czech Lymphoma Study Group. Klin Onkol 2010; 23: 146–154.
   PubMedGoogle Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265.
   PubMed Web of Science ®Google Scholar
• Van Oers MHJ, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non/Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295–3301.
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Sinha R, Byrtek M, et al. The use and effectiveness of Rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer 2014; 120: 1830–1837.
   PubMed Web of Science ®Google Scholar
• Rashidi A, Oak E, Bartlett NL. Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma. Blood 2015; 125:3354–3355.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Feuggier P, et al. Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. Blood 2013; 122:Abstract No 509.
   Web of Science ®Google Scholar
• Jäger U, Fridrik M, Zeitlinger M, et al. Rituximab serum concentrations during immunochemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica 2012; 97: 1431–1438.
   PubMed Web of Science ®Google Scholar
• Müller C, Murawski N, Wiesen MH, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 2012; 119: 3276–3284.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: Final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012; 30: 4462–4469.
   PubMed Web of Science ®Google Scholar
• Jaeger U, Trneny M, Melzer H, et al. Rituximab maintenance significantly prolongs event free (EFS) and progression free survival (PFS) in male patients with aggressive B-cell lymphoma in the NHL13 study. Blood 2013(Suppl): 851.
   PubMed Web of Science ®Google Scholar
• McClanahan F, Hielscher T, Rieger M, et al. Final results of randomized trial comparing 1, 3 or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma. Am J Hematol 2012; 87: E68–E70.
   Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003–4008.
   PubMed Web of Science ®Google Scholar
• Mishra D, Vora J. Non interventional drug studies in oncology: Why we need them? Perspect Clin Res 2010; 1: 128–133.
   PubMedGoogle Scholar
• Hershman DL, Wright JD. Comparative effectiveness research in oncology methodology: observational data. J Clin Oncol 2012; 30: 4215–4222.
   PubMed Web of Science ®Google Scholar
• Gordan LN, Grow WB, Pusateri A, et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005; 23: 1096–1102.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Ladetto M, Boccomini C, et al. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: A phase III randomized study by the Fondazione Italiana Linfomi. J Clin Oncol 2013; 31: 3351–3359.
   PubMed Web of Science ®Google Scholar
• Golay J, Semenzato G, Rambaldi A, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs 2013; 5: 826–837.
   PubMed Web of Science ®Google Scholar